2-Day Seminar Completed | Recording and Pre-Registration Available


$2000 

Seminar Registration Options: *

Learn More


PRE-REGISTRATION AVAILABLE 

If you want to have this training scheduled Live and Exclusively for your company, we will arrange it for you.

Pre-Register now and pay only once the training is scheduled on your preferred days.



Key regulatory documents are continuously updated with the latest U.S. FDA and European Union requirements. As U.S. companies go global, they must meet different product design documentation. The cGMPs mandate Design Control and the Design History File (DHF). In order to sell globally, the EU's CE-marking documentation is a requirement - the Technical File or Design Dossier under the old MDD, and the Technical Documentation requirements of the new MDR. Currently, they serve different purposes and support different goals, but the TD File is moving in the direction of the DHF.

And the DHF is adapting to some of the features of the TD File. And how / where do the DMR and DHR fit?  Being aware of the similarities and differences in the files and their individual documents can further concurrent development and/or updates to both.

WHY YOU SHOULD ATTEND

This seminar will examine the existing and proposed requirements for the U.S. FDA's DHF - including its derivative documents, the DMR, and DHR. It will consider the European Union's new MDR Technical Documentation requirements, which replace the old Technical File / Design Dossier. It will evaluate the documents' differing purposes/goals, as well as the two different device classification schemes, and CE-marking requirements. Required and desirable contents will be discussed. 

Also considered: Areas requiring frequent re-evaluation/update; Similarities and differences; Future trends; Typical DHF Table of Contents; Technical Documentation Table of Contents; The importance and usefulness of the new "General Safety and Performance Requirements" (replacing the old "Essential Requirements"); Structure of the "Declaration of Conformity"; self-declaring or N-B reviewed and changes; parallel approaches to development. Finally, the differing approaches to file audits by the FDA and the Notified Body will be discussed.

WHO SHOULD ATTEND: 

  • Quality Assurance Departments
  • Research and Development Departments
  • Regulatory Affairs Departments
  • Manufacturing Departments
  • Engineering Departments
  • Operations Departments
  • Production Departments
  • Supplements
  • Marketing Departments
  • Documentation Departments

AGENDA

DAY 1 (10 AM to 4 PM)

Lecture 1: 

  • The Design Control requirements of the cGMPs, 21 CFR 820.30
  • Design and Development Planning under ISO 13485:2016 7.3
  • The U.S. FDA's Design History File
  • The EU MDR's Design and Development Process File

Lecture 2: 

  • MDR's "General Safety and Performance Requirements"
  • Device Classification - U.S. FDA vs. EU MDD
  • Design Files' "Typical" Contents

Lecture 3: 

  • The Device Master Record and the Device History Record
  • The "Essential Requirements" and their documentation

Lecture 4: 

  • The remaining elements of a Technical File / Design Dossier
  • DHF / TF, DD Trends

DAY 2 (10 AM to 4 PM)

Lecture 5: 

  • Risk Management / File Under ISO 14971
  • Hazzard Analysis
  • FTA, D-, P-, and U-FMECA's
  • Report

Lecture 6: 

  • Human Factors / Use Engineering Under IEC 62366-1 -2
  • The User Interface
  • The 9 Stages
  • The HF / UE File

Lecture 7: 

  • Putting It All Together
  • Concurrent Compilation of the Files
  • Derivative Documents Development
  • Completion
  • FDA and NB Audit Focus

Lecture 8:

  • Course summary discussion
  • Final Q&A


COURSE DIRECTOR: JOHN E. LINCOLN

John E. Lincoln, is Principal of J. E. Lincoln and Associates LLC, a consulting company with over 36 years experience in U.S. FDA-regulated industries, 22 of which are as an independent consultant. John has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment QMS and software validations, ISO 14971 product risk management files / reports, Design Control / Design History Files, Technical Files, CAPA systems and analysis.

He’s held positions in Manufacturing Engineering, QA, QAE, Regulatory Affairs, to the level of Director and VP (R&D). In addition, John has prior experience in military, government, electronics, and aerospace. He has published numerous articles in peer reviewed journals, conducted workshops and webinars worldwide on CAPA, 510(k)s, risk analysis / management, FDA / GMP audits, validation, root cause analysis, and others. He writes a recurring column for the Journal of Validation Technology. John is a graduate of UCLA.